These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1459314)

  • 21. Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue.
    DeFelippis MR; Bakaysa DL; Bell MA; Heady MA; Li S; Pye S; Youngman KM; Radziuk J; Frank BH
    J Pharm Sci; 1998 Feb; 87(2):170-6. PubMed ID: 9519149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of heparin in realization of the hypoglycaemic action of insulin.
    Kudrjashov BA; Shapiro FB; Ulyanov AM
    Acta Physiol Hung; 1987; 69(2):197-202. PubMed ID: 3303833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes.
    Levy JH; Zaidan JR; Faraj B
    Anesth Analg; 1986 Jul; 65(7):739-42. PubMed ID: 2424341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Action of S 5682 on the complement system. In vitro and in vivo study.
    Di Perri T; Auteri A
    Int Angiol; 1988; 7(2 Suppl):11-5. PubMed ID: 3183451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solubility changes on mixing short- and long-acting insulin preparations.
    Havlik I; Galasko G; Alberts E; Furman KI; Seftel HC
    S Afr Med J; 1988 Mar; 73(6):361-2. PubMed ID: 3281288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of RBCs on the activation of human complement by heparin-protamine complexes.
    Shastri KA; Phillips MJ; Raza S; Logue GL; Rustagi PK
    Blood; 1988 Jan; 71(1):36-40. PubMed ID: 3334899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classical pathway activation during an adverse response to protamine sulphate.
    Best N; Teisner B; Grudzinskas JG; Fisher MM
    Br J Anaesth; 1983 Nov; 55(11):1149-53. PubMed ID: 6605758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of protamine sulphate on erythrocyte agglutination by anti-rh antisera. Cause of time-dependence (author's transl)].
    Franz H; Haustein B; Geske K; Kuropka U; Pfüller U
    Z Immunitatsforsch Immunobiol; 1976; 151(4):350-8. PubMed ID: 820102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absorption of protamine-insulin in diabetic patients. I. Preparation and characterization of protamine-125I-insulin.
    Hansen B; Linde S; Kølendorf K; Jensen F
    Horm Metab Res; 1979 Feb; 11(2):85-90. PubMed ID: 437686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo complement activation by polyanion--polycation complexes: evidence that C5a is generated intravascularly during heparin--protamine interaction.
    Fehr J; Rohr H
    Clin Immunol Immunopathol; 1983 Oct; 29(1):7-14. PubMed ID: 6883814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera.
    Siegel J; Rent R; Gewurz H
    J Exp Med; 1974 Sep; 140(3):631-47. PubMed ID: 4472155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [ELISA detection of protamine antibodies].
    Junker M; Hobler H; Federlin K
    Immun Infekt; 1985 Apr; 13(2):80-2. PubMed ID: 3888823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural studies of a crystalline insulin analog complex with protamine by atomic force microscopy.
    Yip CM; Brader ML; Frank BH; DeFelippis MR; Ward MD
    Biophys J; 2000 Jan; 78(1):466-73. PubMed ID: 10620310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of tumour-induced angiogenesis by systemically administered protamine sulphate.
    Majewski S; Kamiński MJ; Szmurło A; Kamińska G; Malejczyk J
    Int J Cancer; 1984 Jun; 33(6):831-3. PubMed ID: 6203847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel protein cross-linking reaction in stressed Neutral Protamine Hagedorn formulations of insulin.
    Beavis RC; Kneirman MD; Sharknas D; Heady MA; Frank BH; DeFelippis MR
    J Pharm Sci; 1999 Mar; 88(3):331-6. PubMed ID: 10052992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protamine as a barrier against the angiogenic effect of insulin: a possible role of apelin.
    Yeganeh-Hajahmadi M; Mehrabani M; Esmaili M; Farokhi MS; Sanjari M
    Sci Rep; 2023 Oct; 13(1):17267. PubMed ID: 37828117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change in solubility of insulin in therapeutic mixtures of insulin preparations: HPLC analysis.
    Arakawa Y; Kurokawa N; Maeda Y; Yanaihara C
    Diabetes Res Clin Pract; 1989; 7 Suppl 1():S93-100. PubMed ID: 2680372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixing insulins in 1990.
    Anderson JH; Campbell RK
    Diabetes Educ; 1990; 16(5):380-7. PubMed ID: 2202572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [PRACTICAL IDEAS ON THE INSULINS].
    LAURENT C; BOUCHET J
    Montp Med; 1964 Apr; 65():211-22. PubMed ID: 14204440
    [No Abstract]   [Full Text] [Related]  

  • 40. Reduced solubility of short-acting soluble insulins when mixed with longer-acting insulins.
    Nolte MS; Poon V; Grodsky GM; Forsham PH; Karam JH
    Diabetes; 1983 Dec; 32(12):1177-81. PubMed ID: 6360762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.